nsc 338720 has been researched along with Cerebellar Ataxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowman, A; Cummings, J; Dunlop, N; French, R; Jodrell, DI; MacLellan, A; Smyth, JF; Stewart, M | 1 |
| Alberti, D; Arzomanian, R; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Liu, G; Marnocha, R; Tutsch, KD; Van Ummersen, L; Wilding, G | 1 |
2 trial(s) available for nsc 338720 and Cerebellar Ataxia
| Article | Year |
|---|---|
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Picolines; Treatment Failure; Vomiting | 1998 |
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Picolines | 2002 |